Prostate Cancer
Advertisement
Prostate cancer is the 2nd most diagnosed cancer among men worldwide, but the disease lacks established re-treatment options.
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Previous research has shown that the effects of androgen and PSMA receptors can complement each other if used concurrently.
The trial evaluated the data of treatment-naïve patients who underwent RP and received apalutamide as well as ADT.
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Dr. Nyame shared highlights from his presentation on PC screening in high-risk groups as part of an AUA plenary session.
The utility of cADT in patients with prostate cancer with clinical relapse at PSMA PET is unknown.
Investigators found that the NCHT cohort demonstrated increased 3-year bPFS benefits compared to the NHT cohort.
The study group received 6-month neoadjuvant LHRH-α plus abitrexone with prednisone.
Results from the third interim analysis of the DAROL study indicate real-world effectiveness in patients with nmCRPC.
An analysis of the phase 3 ARASENS study revealed new information on PSA responses and their association with outcomes.
A CR was observed in the first patient with mCRPC to receive 2 cycles of 67Cu-SAR-bisPSMA at a dosage of 8GBq.
Dr. Vandekerkhove explains her research on genomic testing in prostate cancer.
The benefits of PSA screening alone are offset by excess negative biopsies and the over-detection of low-grade cancers.
The study sought to determine the outcomes and prevalence related to somatic or germline HRR alterations.
Researchers performed a post hoc analysis on patient data from the randomized, phase 3 LATITUDE trial.
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
Dr. Iagaru discusses the safety findings and clinical implications of his research.
Dr. Ulaner highlights 2 new clinical trials for prostate cancer staging and treatment at Hoag: MIRROR and 177Lu-PNT2002.
The data were sourced from a deidentified US-based metastatic prostate cancer clinicogenomic database.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.